JS07.7.A VISTA IS A CRITICAL AND TARGETABLE IMMUNE CHECKPOINT PATHWAY IN DIFFUSE MIDLINE GLIOMA
Raphaël Collot(Oncode Institute), Alicia Ríos(Princess Máxima Center), Britt M. T. Vervoort(Princess Máxima Center), Hendrikus C. R. Ariese(Oncode Institute), Anoek Zomer(Oncode Institute), Jens Bunt(Princess Máxima Center), Ellen J. Wehrens(Oncode Institute), Dannis G. van Vuurden(Amsterdam UMC Location Vrije Universiteit Amsterdam), Mariëtte E.G. Kranendonk(Princess Máxima Center), Heggert Rebel(Oncode Institute), Esther Hulleman(Amsterdam UMC Location VUmc), Marcel Kool(German Cancer Research Center), Cristian Ruiz-Moreno(Radboud University Nijmegen), Emma Bokobza(Inserm), Amber K. L. Wezenaar(Oncode Institute), Brigit M. te Pas(Princess Máxima Center), H.G. Stunnenberg(Radboud University Nijmegen), Celina Honhoff(Oncode Institute), H. A. Johnson(Princess Máxima Center), Pierre A. Robe(University Medical Center Utrecht)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The whole-genome landscape of medulloblastoma subtypes
|Nature|2017|1.2k
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|Acta Neuropathologica|2012|1k
The changing epidemiology of congenital heart disease
|Nature Reviews Cardiology|2010|757